Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01067729Not ApplicableTerminated

A Postmarket Randomized Study of the Treatment of Superficial Partial-Thickness Burns Using Two Dressings

Role: lead

NCT00964470Not ApplicableUnknown

Multi-Center, Prospective, Randomized, Comparison of AWBAT™-D vs. Xeroform™ or Glucan II™ for Treatment of Donor Sites in Burn Surgery

Role: lead

NCT00974597Not ApplicableTerminated

Comparison of AWBAT™-D and MEPILEX® AG for Treatment of Donor Sites in Burn Surgery

Role: lead

All 3 trials loaded